Saprisartan

Saprisartan

SCHEMBL588531

CCc1nc(C2CC2)c(C(N)=O)n1Cc1ccc2oc(-c3ccccc3NS(=O)(=O)C(F)(F)F)c(Br)c2c1.[KH]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Saprisartan SCHEMBL29813295 0.99
Saprisartan SCHEMBL120388 0.99
SCHEMBL8544117 0.97
SCHEMBL8957327 0.94
SCHEMBL8548685 0.93
SCHEMBL8546004 0.92
SCHEMBL8957280 0.91
SCHEMBL8544800 0.91
SCHEMBL8542117 0.91
SCHEMBL9616353 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020115655-A1 Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders MASSACHUSETTS COLLEGE OF PHARMACY 2002-08-22 US claimed
US-12296085-B2 Method for extracorporeal treatment of preeclampsia and related disorders ImMutriX Therapeutics, Inc. (US) 2025-05-13 US disclosed
EP-3689357-B1 COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME ADVANCED REGEN MEDICAL TECH LLC (US) 2024-12-04 EP disclosed
WO-2024215303-A1 NOVEL DRUG DELIVERY SYSTEMS AND METHODS OF MAKING AND USING SAME THE TEXAS A&M UNIVERSITY SYSTEM (US) 2024-10-17 WO disclosed
EP-4445915-A2 CELL FREE COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME Advanced Regen Medical Technologies, LLC (US) 2024-10-16 EP disclosed
US-20240294909-A1 AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS MERAND PHARMACEUTICALS INC (US) 2024-09-05 US disclosed
US-20240247313-A1 SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2024-07-25 US disclosed
US-11905562-B2 Serotonin transporter gene and treatment of opioid-related disorders UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-02-20 US disclosed
CN-117280030-A Agents, compositions and methods for treating hypoxia and ischemia related conditions 梅兰德制药公司 2023-12-22 CN disclosed
US-20230313196-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS MANSELL JOHN (US) 2023-10-05 US disclosed
US-20020010208-A1 Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid LUITPOLD PHARMACEUTICALS, INC. 2002-01-24 US disclosed
EP-1158973-A2 USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS UNIVERSITY OF CINCINNATI (US) 2001-12-05 EP disclosed
US-6323236-B2 PSYCHOLOGICAL DISORDERS UNIVERSITY OF CINCINNATI 2001-11-27 US disclosed
US-20010023254-A1 Psychological disorders CINCINNATI, UNIVERSITY OF 2001-09-20 US disclosed
US-20010002404-A1 Fatty acid-pharmaceutical agent conjugates LUITPOLD PHARMACEUTICALS, INC. 2001-05-31 US disclosed
WO-2000050020-A2 USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS UNIVERSITY OF CINCINNATI (US) 2000-08-31 WO disclosed
WO-1999030690-A1 ORAL DELIVERY FORMULATION AXIA THERAPEUTICS, INC. (US) 1999-06-24 WO disclosed
EP-0909183-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES Neuromedica, Inc. (US) 1999-04-21 EP disclosed
US-5795909-A ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS NEUROMEDICA, INC. (US) 1998-08-18 US disclosed
WO-1997044063-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES NEUROMEDICA, INC. (US) 1997-11-27 WO disclosed